Intracellular Historical Income Statement

ITCI Stock

USD 85.69 0.24 0.28%

Historical analysis of Intracellular income statement accounts such as Gross Profit of 452.2 M or Research Development of 189.1 M can show how well Intracellular Th performed in making a profits. Evaluating Intracellular income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Intracellular's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Intracellular Th latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Intracellular Th is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

About Intracellular Income Statement Analysis

Intracellular Th Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Intracellular shareholders. The income statement also shows Intracellular investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Intracellular Income Statement Chart

As of now, Intracellular's Research Development is increasing as compared to previous years. The Intracellular's current Cost Of Revenue is estimated to increase to about 43.9 M, while Operating Income is projected to decrease to (167.4 M).

Research Development Selling General Administrative Other Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Intracellular Th. It is also known as Intracellular overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Intracellular's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Intracellular Th current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

	2021	2022	2023	2024 (projected)
Net Interest Income	1.6M	7.4M	20.3M	21.4M
Interest Income	1.6M	7.4M	20.3M	21.4M

Net Interest Income Interest Income

Intracellular income statement Correlations

	Interest Expense	Total Revenue	Gross Profit	Operating Income	Research Development	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Ebit	Ebitda	Total Operating Expenses	Total Other Income Expense Net	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Interest Expense		0.72	0.73	-0.56	0.72	-0.14	-0.52	-0.52	0.29	0.64	0.73	0.78	-0.56	-0.56	0.78	0.72	-0.51	0.68	0.31	0.7	0.7	0.72	-0.6	0.63
Total Revenue	0.72		0.98	-0.38	0.77	-0.09	-0.32	-0.32	0.45	0.48	0.83	0.92	-0.38	-0.38	0.91	0.91	-0.32	0.7	0.46	0.92	0.93	0.63	-0.88	0.86
Gross Profit	0.73	0.98		-0.34	0.69	-0.21	-0.29	-0.29	0.44	0.44	0.83	0.89	-0.35	-0.35	0.88	0.85	-0.29	0.61	0.45	0.87	0.88	0.6	-0.86	0.85
Operating Income	-0.56	-0.38	-0.34		-0.69	-0.13	1.0	1.0	-0.09	-0.93	-0.77	-0.71	1.0	1.0	-0.73	-0.44	0.99	-0.64	-0.12	-0.38	-0.29	-0.87	0.18	-0.63
Research Development	0.72	0.77	0.69	-0.69		0.38	-0.65	-0.65	0.36	0.71	0.74	0.88	-0.68	-0.68	0.88	0.89	-0.62	0.92	0.39	0.86	0.81	0.69	-0.67	0.71
Cost Of Revenue	-0.14	-0.09	-0.21	-0.13	0.38		-0.11	-0.11	0.04	0.16	-0.18	-0.01	-0.1	-0.1	-0.01	0.24	-0.08	0.49	0.06	0.22	0.15	-0.01	-0.02	-0.18
Income Before Tax	-0.52	-0.32	-0.29	1.0	-0.65	-0.11		1.0	-0.06	-0.92	-0.74	-0.67	0.99	0.99	-0.68	-0.38	0.99	-0.6	-0.09	-0.32	-0.22	-0.85	0.12	-0.59
Net Income	-0.52	-0.32	-0.29	1.0	-0.65	-0.11	1.0		-0.06	-0.92	-0.74	-0.67	0.99	0.99	-0.68	-0.38	0.99	-0.6	-0.1	-0.32	-0.23	-0.85	0.12	-0.59
Income Tax Expense	0.29	0.45	0.44	-0.09	0.36	0.04	-0.06	-0.06		0.1	0.29	0.38	-0.09	-0.09	0.37	0.41	-0.06	0.23	1.0	0.42	0.43	0.19	-0.46	0.32
Depreciation And Amortization	0.64	0.48	0.44	-0.93	0.71	0.16	-0.92	-0.92	0.1		0.81	0.76	-0.94	-0.94	0.77	0.55	-0.93	0.76	0.13	0.51	0.42	0.95	-0.22	0.67
Selling General Administrative	0.73	0.83	0.83	-0.77	0.74	-0.18	-0.74	-0.74	0.29	0.81		0.96	-0.78	-0.78	0.96	0.73	-0.75	0.69	0.31	0.71	0.67	0.91	-0.6	0.94
Other Operating Expenses	0.78	0.92	0.89	-0.71	0.88	-0.01	-0.67	-0.67	0.38	0.76	0.96		-0.72	-0.72	1.0	0.88	-0.67	0.8	0.4	0.86	0.83	0.85	-0.74	0.92
Ebit	-0.56	-0.38	-0.35	1.0	-0.68	-0.1	0.99	0.99	-0.09	-0.94	-0.78	-0.72		1.0	-0.73	-0.43	1.0	-0.63	-0.12	-0.38	-0.28	-0.88	0.17	-0.64
Ebitda	-0.56	-0.38	-0.35	1.0	-0.68	-0.1	0.99	0.99	-0.09	-0.94	-0.78	-0.72	1.0		-0.73	-0.43	1.0	-0.63	-0.12	-0.38	-0.28	-0.88	0.17	-0.64
Total Operating Expenses	0.78	0.91	0.88	-0.73	0.88	-0.01	-0.68	-0.68	0.37	0.77	0.96	1.0	-0.73	-0.73		0.87	-0.68	0.81	0.39	0.86	0.82	0.85	-0.73	0.92
Total Other Income Expense Net	0.72	0.91	0.85	-0.44	0.89	0.24	-0.38	-0.38	0.41	0.55	0.73	0.88	-0.43	-0.43	0.87		-0.36	0.88	0.43	1.0	0.98	0.63	-0.88	0.7
Net Income From Continuing Ops	-0.51	-0.32	-0.29	0.99	-0.62	-0.08	0.99	0.99	-0.06	-0.93	-0.75	-0.67	1.0	1.0	-0.68	-0.36		-0.58	-0.09	-0.3	-0.21	-0.86	0.1	-0.6
Non Operating Income Net Other	0.68	0.7	0.61	-0.64	0.92	0.49	-0.6	-0.6	0.23	0.76	0.69	0.8	-0.63	-0.63	0.81	0.88	-0.58		0.26	0.86	0.8	0.75	-0.6	0.59
Tax Provision	0.31	0.46	0.45	-0.12	0.39	0.06	-0.09	-0.1	1.0	0.13	0.31	0.4	-0.12	-0.12	0.39	0.43	-0.09	0.26		0.44	0.45	0.21	-0.47	0.33
Interest Income	0.7	0.92	0.87	-0.38	0.86	0.22	-0.32	-0.32	0.42	0.51	0.71	0.86	-0.38	-0.38	0.86	1.0	-0.3	0.86	0.44		0.99	0.6	-0.89	0.7
Net Interest Income	0.7	0.93	0.88	-0.29	0.81	0.15	-0.22	-0.23	0.43	0.42	0.67	0.83	-0.28	-0.28	0.82	0.98	-0.21	0.8	0.45	0.99		0.54	-0.92	0.67
Reconciled Depreciation	0.72	0.63	0.6	-0.87	0.69	-0.01	-0.85	-0.85	0.19	0.95	0.91	0.85	-0.88	-0.88	0.85	0.63	-0.86	0.75	0.21	0.6	0.54		-0.39	0.77
Extraordinary Items	-0.6	-0.88	-0.86	0.18	-0.67	-0.02	0.12	0.12	-0.46	-0.22	-0.6	-0.74	0.17	0.17	-0.73	-0.88	0.1	-0.6	-0.47	-0.89	-0.92	-0.39		-0.6
Selling And Marketing Expenses	0.63	0.86	0.85	-0.63	0.71	-0.18	-0.59	-0.59	0.32	0.67	0.94	0.92	-0.64	-0.64	0.92	0.7	-0.6	0.59	0.33	0.7	0.67	0.77	-0.6

Click cells to compare fundamentals

Intracellular Account Relationship Matchups

Intracellular income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	6.8M	4.8M	2.1M	7.4M	8.5M	8.9M
Total Revenue	60.6K	22.5M	81.7M	249.1M	464.4M	487.6M
Gross Profit	60.6K	20.6M	73.7M	228.7M	430.6M	452.2M
Operating Income	(154.0M)	(231.2M)	(285.7M)	(263.6M)	(159.4M)	(167.4M)
Research Development	89.1M	65.8M	88.8M	134.7M	180.1M	189.1M
Cost Of Revenue	89.1M	1.9M	8.0M	20.4M	33.7M	43.9M
Income Before Tax	(147.7M)	(227.0M)	(284.1M)	(256.3M)	(139.0M)	(146.0M)
Net Income Applicable To Common Shares	(147.7M)	(227.0M)	(284.1M)	(256.3M)	(230.6M)	(219.1M)
Net Income	(147.7M)	(227.0M)	(284.1M)	(256.3M)	(139.7M)	(146.7M)
Depreciation And Amortization	477.1K	528.1K	533.4K	656K	528K	342.7K
Selling General Administrative	64.9M	186.4M	272.6M	358.8M	317.7M	333.5M
Other Operating Expenses	154.1M	253.8M	367.4M	512.8M	623.8M	654.9M
Ebit	(154.0M)	(231.2M)	(285.7M)	(263.6M)	(159.4M)	(167.4M)
Ebitda	(153.5M)	(230.7M)	(285.2M)	(263.0M)	(158.9M)	(166.8M)
Total Operating Expenses	154.1M	251.9M	359.4M	492.3M	590.0M	619.5M
Total Other Income Expense Net	6.3M	4.2M	1.6M	7.4M	20.3M	21.4M
Net Income From Continuing Ops	(147.7M)	(227.0M)	(284.1M)	(256.3M)	(139.7M)	(146.7M)
Non Operating Income Net Other	6.3M	4.2M	1.6M	7.4M	8.5M	8.9M
Interest Income	6.3M	4.2M	1.6M	7.4M	20.3M	21.4M
Net Interest Income	6.3M	4.2M	1.6M	7.4M	20.3M	21.4M
Reconciled Depreciation	477.1K	528.1K	533.4K	656K	528K	519.4K

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:

How To Invest In Intracellular

Details

Is Intracellular Stock a good investment?

Details

What is Intracellular's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.87)

Revenue Per Share

6.096

Quarterly Revenue Growth

0.39

Return On Assets

(0.07)

Return On Equity

(0.1)

The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Intracellular Historical Income Statement

About Intracellular Income Statement Analysis

Intracellular Income Statement Chart

Other Operating Expenses

Intracellular income statement Correlations

Intracellular Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Intracellular income statement Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Net Income	+ 1.0	Income Before Tax
Tax Provision	+ 1.0	Income Tax Expense

Ebitda	- 0.94	Depreciation And Amortization
Ebit	- 0.94	Depreciation And Amortization
Net Income From Continuing Ops	- 0.93	Depreciation And Amortization
Depreciation And Amortization	- 0.93	Operating Income
Extraordinary Items	- 0.92	Net Interest Income
Depreciation And Amortization	- 0.92	Net Income